Senior executives

CombiGene’s senior executives are the Company’s CEO Jan Nilsson, the Company’s Chief Research and Development Officer Karin Agerman and Louise Aspenberg, Chief Financial Officer. The senior executives are listed below with information about year of birth, when they took office, experience, current and previous assignments over the last five years, holdings in other companies in which they are active and holdings in the Company. “Holdings in the Company” refer to own and/or related parties’ holdings.

Jan Nilsson, CEO

CEO since 2016. (Born 1949)
Education and experience: Jan Nilsson has an MA from the University of Gothenburg and an MBA from Uppsala University. Jan was appointed CEO of CombiGene on 1 October 2016. He has long-standing experience from large pharmaceutical companies and biotech firms. He has also been active in several different areas in the pharmaceutical industry such as pharmaceuticals development and the launch, sales and marketing of established international brands. He also has a solid management background, having served as CEO of both private and public-sector companies.
Current assignments: Board member of CanImGuide Therapeutics AB, CarryGenes Therapeutics AB, Urbicum Ledningskonsult AB and Immodulate Pharma AB.
Previous assignments: CEO of NeuroVive Pharmaceutical AB.
Owner and active in the following companies: Urbicum Ledningskonsult AB.
Own and/or related parties’ holdings in the Company: 1 100 000 shares.

Karin Agerman, Chief Research and Development Officer

Chief Research and Development Officer since 2018. (Born 1973)
Education and experience: Karin Agerman has a PhD in molecular neurobiology from Karolinska Institutet and more than fifteen years of experience in the international pharmaceutical industry and the start-up arena in Sweden. She has worked for such companies as AstraZeneca, Merck and Uppsala BIO, and has been active in a number of senior positions. Areas in which she has been active include preclinical development, marketing and financing. Her contact network is broad in both industry and academia, as well as in the sphere of Swedish government agencies.
No current assignments.
No previous assignments over the last five years.
She has been neither owner nor active in any companies over the last five years.
Own and/or related parties’ holdings in the Company: No holdings in shares or warrants.

Louise Aspenberg, Chief Financial Officer

Chief Financial Officer since 2020. (born 1976)
Education and experience: Louise Aspenberg has completed the International Economics Programme at Örebro University. Louise is an experienced economist with broad experience from financial and economic tasks. Louise has worked at Relation & Brand, which during the years 2006-2013 was listed on Aktietorget (now Spotlight Stock Market). Louise has a solid knowledge in consolidated financial statements and financial reporting for public companies.

No current assignments.
No previous assignments over the last five years.
She has been neither owner nor active in any companies over the last five years.
Own and/or related parties’ holdings in the Company: No holdings in shares or warrants.

Other employees

Annika Ericsson, Preclinical Project Manager

Senior Project Manager since 2018. (Born 1974)
Education and experience: Annika Ericsson holds a PhD in medical biochemistry from Karolinska Institutet. Her thesis topic concerned enzyme and gene therapy for acute intermittent porphyria. She has postdoc experience from Mount Sinai School of Medicine in New York and 14 years of experience in the biotech industry, having worked with Zymenex A/S and Chiesi. She has worked with lab and development work and upscaling of the production process for protein drugs, and has worked as project manager for preclinical studies of lysosomal storage disorders. Annika has broad experience of planning, organizing and conducting large research projects.

Martin Linhult, Project Manager CMC

Project Manager CMC since 2020. (Born 1972)
Education and experience: Martin Linhult holds a PhD in molecular biology at Royal Institute of Technology (KTH) in Stockholm (1998-2003) and holds a Master of Chemical Engineering from the same university. In addition, Martin has extensive experience from a number of senior positions in the Swedish pharmaceutical industry and is used to interacting with regulatory authorities at an international level, including the FDA and EMA. Martin has worked in all parts of the production process of biological drugs and was responsible for building up the production unit at Octapharma.

Pernilla Fagergren, Clinical Project Manager

Clinical Project Manager since 2021. (born 1970)
Education and experience:
Pernilla Fagergren has a broad experience from academia and industry. She holds a PhD at Karolinska Institutet in Stockholm and has conducted research at Mount Sinai School of Medicine in New York, USA. Pernilla comes most recently from Merck AB where she worked as a medical advisor and manager in neurology. Prior to that, she worked as a researcher with early pharmaceutical projects at Karo Bio AB. Her expertise covers key areas such as drug development, project management and neuropharmacology. Pernilla has throughout her carrier been collaborating with national and international physicians and leading medical opinion leaders.

Esbjörn Melin, PhD, Industrial post doc

Industrial post doc since 2021. (born 1987)
Education and experience: Esbjörn Melin has a PhD in the field of gene therapeutic treatment of epilepsy at Lund University (2014-2020) and holds a Master’s degree in nanoengineering. As a PhD student, Esbjörn worked closely with Professor Merab Kokaia, one of CombiGene’s scientific founders.

Daniela Morath, Corporate Administration

Corporate Administration since 2018. (Born 1980)
Education and experience: Daniela Morath has completed a natural sciences programme and has a higher vocational education diploma in 3D printing. She has several years of experience of administrative duties in various industries and has also worked for a couple of years with business administration and salary administration. Daniela has worked both in larger companies in the industry sector and in smaller service-oriented companies, which has given her experience of different administrative processes.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook